Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672481 | 0.79 | LMNA (0.66) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL30011535 | 0.79 | MAPT (0.47) | CYP1A2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL28602639 | 0.79 | MAPT (0.47) | CYP1A2MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL11491925 | 0.76 | LMNA (0.61) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL19086928 | 0.76 | LMNA (0.61) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL9306872 | 0.76 | RAB9A (0.58) | LMNAMAPTSMN1; SMN2CASP3SENP7 | |
| SCHEMBL353166 | 0.76 | LMNA (0.61) | LMNACYP1A2MAPTTHRBALOX15 | |
| Zoxazolamine SCHEMBL10891033 | 0.76 | LMNA (1.00) | LMNACYP1A2MAPTTHRBALOX15 | |
| SCHEMBL19597624 | 0.76 | LMNA (0.61) | LMNACYP1A2MAPTTHRBALOX15 | |
| Chlorzoxazone SCHEMBL35177 | 0.76 | KDM4E (0.70) | LMNACYP1A2MAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213081-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-07-07 | — | — | US | disclosed |
| US-20220213081-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-07-07 | — | — | US | disclosed |
| US-20220119377-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-04-21 | — | — | US | disclosed |
| US-11214568-B2 | Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-01-04 | — | — | US | disclosed |
| US-11214568-B2 | Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3699173-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | California Institute of Technology (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3699173-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | California Institute of Technology (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200199114-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-06-25 | — | — | US | disclosed |
| US-20200199114-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-06-25 | — | — | US | disclosed |
| US-5347008-A | Thio(cyclo) alkanepolycarboxylic acids containing heterocyclic substituents | CIBA-GEIGY CORPORATION (US) | 1994-09-13 | — | — | US | disclosed |
| US-5152929-A | Corrosion inhibitors for water systems | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0129506-A2 | Heterocyclically substituted thio(cyclo)alkane polycarboxylic acids | CIBA-GEIGY AG (CH) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213081-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | GMNN, GRIA1, GRIA2 | LMNA 2903/4885CYP1A2 211/4885MAPT 2373/4885 |
| US-20200199114-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | GMNN, GRIA1, GRIA2 | LMNA 2903/4885CYP1A2 211/4885MAPT 2373/4885 |
| US-20220119377-A1 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME | GMNN, GRIA1, GRIA2 | LMNA 2903/4885CYP1A2 211/4885MAPT 2373/4885 |
| US-11214568-B2 | Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same | GMNN, GRIA1, GRIA2 | LMNA 2903/4885CYP1A2 211/4885MAPT 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.